Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

CARISMA Therapeutics Q4 EPS $(0.52) Beats $(0.55) Estimate, Sales $4.29M Beat $2.90M Estimate

Author: Benzinga Newsdesk | April 01, 2024 10:05am

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.55) by 5.45 percent. The company reported quarterly sales of $4.29 million which beat the analyst consensus estimate of $2.90 million by 47.90 percent.

Posted In: CARM